1.735
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy - Yahoo Finance
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell Microcap Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell Small Cap Completeness Index - marketscreener.com
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of - The National Law Review
NMRA Slides As Neumora Kills Navacaprant After Phase 3 Blowup - StocksToTrade
NMRA Stock Drops As Neumora Axes Failed Depression Drug - timothysykes.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000 Index - marketscreener.com
NMRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the - TMX Newsfile
Price to book forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
NMRA Slides As Neumora Axes Navacaprant After Phase 3 Failure - timothysykes.com
Price to sales forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Enterprise value to EBIT forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Price to earnings forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Price to sales forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Enterprise value to EBITDA forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Price to earnings forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Enterprise value to revenue forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Neumora Therapeutics, Inc. Actuals & Estimates (NASDAQ:NMRA) - TradingView
NMRA Forecast — Price Target — Prediction for 2027 - TradingView
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Stocktwits
Neumora stock plunges 49% after late-stage depression drug failure - MSN
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Neumora stock price target lowered to $4 by Mizuho on trial failure - Investing.com
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds - The National Law Review
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pinto Joshua - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Aurora Daljit Singh - Moomoo
Neumora Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer BERNS PAUL L - Moomoo
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud - Business Wire
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Rx Rundown: Sanofi, Neumora Therapeutics, Uniqure and more - Medical Marketing and Media
Neumora Therapeutics Inc (NMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neumora Therapeutics Inc (NMRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neumora Therapeutics Inc (NMRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors - GuruFocus
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics, Inc. (NMRA) for Potential Securities Fraud - ACCESS Newswire
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data - Yahoo Finance
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations – Company AnnouncementFT.com - Financial Times
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) - PR Newswire
Neumora Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics, Inc. (NMRA) - ACCESS Newswire
Kappa Opioid Antidepressant Navacaprant Goes 0-for-3 in Phase 3: Neumora Cuts 35% of Staff - Tech Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Three pivotal MDD trial failures for Neumora lead to staffing cuts - Yahoo Finance
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure - The Globe and Mail
Neumora scraps depression drug, cuts 35% of staff, refocuses pipeline - Stock Titan
NMRA Maintains Buy Rating by Needham -- Price Target Lowered to $5.00 - GuruFocus
Neumora Pivots To Broader Pipeline After Navacaprant Fails In MDD - Citeline News & Insights
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Needham cuts Neumora stock price target on navacaprant discontinuation - Investing.com
Needham cuts Neumora stock price target on navacaprant discontinuation By Investing.com - Investing.com Canada
Neumora stock price target cut to $7 on failed trial, H.C. Wainwright maintains buy - Investing.com Canada
Neumora Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Neumora bins depression drug after Phase III failures - The Pharma Letter
Neumora depression drug fails; EnGene to cut 50% of staff - Yahoo Finance
NMRA stock on track for worst day in 1.5 years — Neumora Therapeutics' lead depression drug fails late stage trials - MSN
Neumora ends depression drug programme and announces workforce reduction (NMRA) - MSN
William Blair Maintains Neumora Therapeutics(NMRA.US) With Buy Rating - Moomoo
Neumora plummets as phase 3 navacaprant data misses key goal - MSN
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):